"Kombina\u010Dn\u00ED terapie peror\u00E1ln\u00EDmi antidiabetiky - kombinace deriv\u00E1t\u016F sulfonylurey a metforminu" . . "Kombina\u010Dn\u00ED terapie peror\u00E1ln\u00EDmi antidiabetiky - kombinace deriv\u00E1t\u016F sulfonylurey a metforminu"@cs . "Honka, Marek" . . "peroral antidiabetics; sulphonylurea; metformin; type 2 diabetes mellitus"@en . "Combined therapy with peroral antidiabetics \u2013 sulphonylurea derivates \u2013 and metformin"@en . "Pathogenesis of type 2 diabetes mellitus is of a complex nature, involving the following basic factors: insulin resistance and insulin secretion disorders. Temporary efficiency of treatment strategies based on monotherapy with peroral antidiabetics is due to the progressive nature of the disease resulting from decreased \u00DF cell secretion capacity. The effect of metformin is based on a decrease in liver glucose production and and increase in insulin sensitivity of muscle tissue. Not only is it effectivein the reduction of HBA1a and microvascular complications in the treatment of type 2 diabetes and, but also reduces the occurrence of cardiovascular events, the reason why it is the first choice drug for all type 2 diabetes patients in the absence of counter-indications. Derivates of sulphonylurea have a positive influence on another key disorder in the pathogenesis of type 2 diabetes, i.e. disturbed insulin secretion. Hypoglycaemia is the only significant adverse of its application."@en . "8"^^ . "52" . . . . "[9E58BA5CCC8E]" . . "Vnit\u0159n\u00ED l\u00E9ka\u0159stv\u00ED" . "Suppl.3" . "V" . "CZ - \u010Cesk\u00E1 republika" . . "Patogeneze diabetes mellitus 2. typu m\u00E1 komplexn\u00ED charakter se sv\u00FDmi z\u00E1kladn\u00EDmi slo\u017Ekami: inzulinovou rezistenc\u00ED a poruchou sekrece inzulinu. P\u0159irozen\u00FD progresivn\u00ED charakter onemocn\u011Bn\u00ED dan\u00FD poklesem sekre\u010Dn\u00ED schopnosti \u00DF-bu\u0148ky je p\u0159\u00ED\u010Dinou do\u010Dasn\u00E9 efektivity l\u00E9\u010Debn\u00FDch sch\u00E9mat zalo\u017Een\u00FDch pouze na monoterapii peror\u00E1ln\u00EDmi antidiabetiky. Metformin p\u016Fsob\u00ED prost\u0159ednistv\u00EDm sn\u00ED\u017Een\u00ED jatern\u00ED produkce gluk\u00F3zy a zv\u00FDen\u00EDm citlivosti inzulinu ve svalov\u00E9 tk\u00E1ni. V l\u00E9\u010Db\u011B diabetu 2. typu je efektivn\u00ED nejen v redukci HBA1c a mikrovakul\u00E1rn\u00EDch komplikac\u00ED, ale nav\u00EDc jeho u\u017Eit\u00ED sni\u017Euje v\u00FDskyt kardiovaskul\u00E1rn\u00EDch p\u0159\u00EDhod, proto je metformin p\u0159i nep\u0159\u00EDtomnosti kontraindikac\u00ED l\u00E9kem prvn\u00ED volby pro v\u0161echny nemocn\u00E9 s diabetem 2. typu. Deriv\u00E1ty sulfonylurey ovliv\u0148uj\u00ED p\u0159\u00EDzniv\u011B dal\u0161\u00ED kl\u00ED\u010Dovou poruchu v patogenezi diabetu 2. typu: poru\u0161enou sekreci inzulinu. Jedin\u00FDm v\u00FDznamn\u00FDm ne\u017E\u00E1douc\u00EDm \u00FA\u010Dinkem p\u0159i jejich pod\u00E1v\u00E1n\u00ED jsou hypoglykemie." . "481934" . "Combined therapy with peroral antidiabetics \u2013 sulphonylurea derivates \u2013 and metformin"@en . "1"^^ . "RIV/00843989:_____/06:00013797!RIV09-MZ0-00843989" . . "1"^^ . "Kombina\u010Dn\u00ED terapie peror\u00E1ln\u00EDmi antidiabetiky - kombinace deriv\u00E1t\u016F sulfonylurey a metforminu" . . "0042-773X" . . "Patogeneze diabetes mellitus 2. typu m\u00E1 komplexn\u00ED charakter se sv\u00FDmi z\u00E1kladn\u00EDmi slo\u017Ekami: inzulinovou rezistenc\u00ED a poruchou sekrece inzulinu. P\u0159irozen\u00FD progresivn\u00ED charakter onemocn\u011Bn\u00ED dan\u00FD poklesem sekre\u010Dn\u00ED schopnosti \u00DF-bu\u0148ky je p\u0159\u00ED\u010Dinou do\u010Dasn\u00E9 efektivity l\u00E9\u010Debn\u00FDch sch\u00E9mat zalo\u017Een\u00FDch pouze na monoterapii peror\u00E1ln\u00EDmi antidiabetiky. Metformin p\u016Fsob\u00ED prost\u0159ednistv\u00EDm sn\u00ED\u017Een\u00ED jatern\u00ED produkce gluk\u00F3zy a zv\u00FDen\u00EDm citlivosti inzulinu ve svalov\u00E9 tk\u00E1ni. V l\u00E9\u010Db\u011B diabetu 2. typu je efektivn\u00ED nejen v redukci HBA1c a mikrovakul\u00E1rn\u00EDch komplikac\u00ED, ale nav\u00EDc jeho u\u017Eit\u00ED sni\u017Euje v\u00FDskyt kardiovaskul\u00E1rn\u00EDch p\u0159\u00EDhod, proto je metformin p\u0159i nep\u0159\u00EDtomnosti kontraindikac\u00ED l\u00E9kem prvn\u00ED volby pro v\u0161echny nemocn\u00E9 s diabetem 2. typu. Deriv\u00E1ty sulfonylurey ovliv\u0148uj\u00ED p\u0159\u00EDzniv\u011B dal\u0161\u00ED kl\u00ED\u010Dovou poruchu v patogenezi diabetu 2. typu: poru\u0161enou sekreci inzulinu. Jedin\u00FDm v\u00FDznamn\u00FDm ne\u017E\u00E1douc\u00EDm \u00FA\u010Dinkem p\u0159i jejich pod\u00E1v\u00E1n\u00ED jsou hypoglykemie."@cs . "RIV/00843989:_____/06:00013797" . . . . "Kombina\u010Dn\u00ED terapie peror\u00E1ln\u00EDmi antidiabetiky - kombinace deriv\u00E1t\u016F sulfonylurey a metforminu"@cs . . .